Stock 4502 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Takeda Pharmaceutical Company Limited Fukuoka Stock Exchange

Equities

4502

JP3463000004

Delayed Fukuoka Stock Exchange
Other stock markets
 05:55:26 17/04/2024 am IST 		5-day change 1st Jan Change
4,080 JPY -1.21% Intraday chart for Takeda Pharmaceutical Company Limited -.--% +2.13%
18/06 Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP MT
18/06 Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company appears to be poorly valued given its net asset value.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analyst opinion has improved significantly over the past four months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • One of the major weak points of the company is its financial situation.
  • With an expected P/E ratio at 45.48 and 62.57 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
+2.13% 41.43B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+52.93% 797B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.55% 628B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.08% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.40% 323B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.58% 300B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.13% 244B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+1.39% 223B
A+
AMGEN INC. Stock Amgen Inc.
+6.24% 163B
C+
PFIZER, INC. Stock Pfizer, Inc.
-4.79% 153B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. 4502 Stock
  5. Ratings Takeda Pharmaceutical Company Limited